1.In Jan, 1994, the contract and the articles of association were officially signed to establish QINGYUAN BLUE TREASURE PHARMACEUTICALS CO., LTD.
2.In Feb, 1994,Qingyuan Blue Treasure Pharmaceutical Co., Ltd. was founded.
3.In Jan, 1996, the company was the first in china to obtain the new drug certificate and production permit for Lovastatin .
4.In 1996, Lovastatin project was included in the national Torch Plan and was rated as one of the key new products of Guangdong. Meanwhile, the company was recognized as a technologically advanced foreign-invested enterprise.
5.In Jun, 1996, the company was renamed as GUANGDONG BLUE TREASURE PHARMACEUTICALS CO., LTD.
6.In Dec, 1998, the company was accredited as a High-tech enterprise in Guangdong.
7.In Dec, 1998, Lovastatin project passed the appraisal of the National Torch Plan. It was the first project in Qingyuan city to pass such appraisal.
8.In Apr, 1999,Mevastatin was put into production successfully.
9.In May, 2000, Pravastatin was put into production successfully, and the Pravastatin project was included in “100 science and technology engineering projects of Guangdong Province”.
10.In Feb, 2003, BT was issued with the Certificate of Good Manufacturing Practices for Human Drugs by the State Food and Drug Administration (China).
11.In Nov, 2004, BT was accredited as a knowledge-intense and technology-intense enterprise in Guangdong Province.
12.In Jul, 2005, the technical reconstruction project of Pravastatin was started, and was successfully, completed in Oct, 2006. It was a key project of the largest scale and investment amount in the history of BT.
13.In Dec, 2007, the shareholders reinvested RMB 30.21 million Yuan in the Company. Thus, the total registered capital was increased to USD 7.53 million and the total investment to USD 8.53 million.
14.In Aug, 2008, the Company introduced a new immunosuppressant intermediate- mycophenolic acid (MPA).
15.In Nov, 2008, the validation conducted by the Australian Therapeutic Goods Administration (TGA) for Pravastatin Sodium was approved.
16.In Jul, 2009, the validation conducted by the U.S. Food and Drug Administration (FDA) for Pravastatin Sodium was approved.
17.For the API-Pravastatin Sodium, U.S. FDA cGMP re-inspection was passed in September 2013.
18.For the API-Pravastatin Sodium, TGA cGMP re-inspection was passed in March 2014.
19.For the API-Pravastatin Sodium, U.S. FDA cGMP re-inspection was passed in April 2016.
20.Groundbreaking ceremony for the new plant was held in Shijiao, Qingyuan in December 2017.

 

 

 

版权所有©广东蓝宝制药有限公司保留一切权利。 
粤公网安备 44180202000306号  网站备案:粤ICP备16104045号 互联网药品信息服务资格证书(粤)—非经营性—2021—0443